You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 50 No. 12, December 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  Letters To The Editor
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Euphorogenic Properties of the Serotonergic Partial Agonist m-Chlorophenylpiperazine in Cocaine Addicts

Laure Buydens-Branchey, MD
VA Medical Center Brooklyn, NY 11209

Marc Branchey, MD; Paul Fergeson, MA
Jeffrey Hudson

Craig McKernin, PA
Brooklyn, NY

Arch Gen Psychiatry. 1993;50(12):1001-1002.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The role played by alterations in serotonergic function in cocaine addiction is mostly unexplored in humans. To explore this, we studied the behavioral, physiological, and endocrine responses of cocaine addicts to challenges with either a placebo or with the serotonin partial agonist m-chlorophenylpiperazine hydrochloride (m-CPP). Nineteen patients who were in good physical health, whose drug of choice was cocaine and had used it almost exclusively during the year preceding our study, and who met DSM-III-R diagnostic criteria for cocaine dependence or abuse were included in the study. Their mean (±SD) age was 35.1 ±7.2 years. They were tested after admission to our inpatient drug rehabilitation unit. The mean (±SD) number of days elapsed since drug discontinuation was 15.1 ±6.6. Patients received m-CPP (0.5 mg/kg) or placebo in identical capsules, in random sequence, at 9:30 AM, with a 2-day interval between test days and according to a double-blind . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.